CMSC DAILY DIGEST: Official Reports from the 2014 Cooperative Meeting of CMSC and ACTRIMS
Saturday, May 31, 2014
Photos of the day’s events included with each article!
|
|
|
| This Morning’s Symposia Schedule: From Pediatric MS To Plasma Exchange in CNS Demyelinating Diseases
Symposia being conducted at this morning’s session of the 2014 Cooperative Meeting of CMSC and ACTRIMS cover a broad array of topics, ranging from Gender Issues in MS and Pediatric MS to Controversies in Multiple Sclerosis, Assessing Risk Tolerance to DMTs: Understanding and Educating About Safety, and Plasma Exchange for CNS Demyelinating Diseases. The symposia will run concurrently from 9 a.m. to noon…. Read More |
 Brenda Banwell, MD, FAAP, FRCPC |
|
|
|
| Exclusive Preview of the 2014 Donald Paty Memorial Lecture
The CMSC Donald Paty Memorial Lecture is a high point of the 2014 Cooperative Meeting of CMSC and ACTRIMS. The annual lecture honors the late Donald Winston Paty, MD (1936-2004), a leader in multiple sclerosis research and clinical care remembered for – among many other contributions – his pioneering work in neuroimaging…. Read More |
 Teresa Frohman, PA-C and Elliot Frohman, MD, PhD |
|
|
|
| DMTs Necessitate Enhanced Ability To Recognize, Manage Opportunistic Infections
The availability of 11 disease-modifying therapies (DMTs) and the imminent arrival of several more make it imperative that neurologists and other clinicians caring for patients with multiple sclerosis (MS) become better versed in recognizing and managing the opportunistic infections that can emerge in the setting of immunomodulation. This is an important component of any risk-benefit analysis…Â Read More |
 Patricia K. Coyle, MD |
|
|
|
| New NMO Diagnostic Criteria to Focus on Biomarker, Reflect Breadth of Presentations
New diagnostic criteria for neuromyelitis optica (NMO) that place greater emphasis on whether a biomarker is detected are expected later this year. The new criteria permit a confident diagnosis of NMO after a single symptom in some patients and, hence, the initiation of optimal therapies for the autoimmune disorder, Brian G. Weinshenker, MD, FRCP (C) told attendees at a symposium yesterday at the 2014 Cooperative Meeting of CMSC and ACTRIMS in Dallas, TX…Â Read More |
 Brian G. Weinshenker, MD, FRCP (C) |
|
|
|
| MRI-Derived Insights Call for Revisiting Approaches to Treating MS
The diagnostic and prognostic utility of magnetic resonance imaging (MRI) in multiple sclerosis (MS) calls into question long-accepted dictums of MS care and even challenges fundamental notions of the nature of the disease and its treatment, Robert T. Naismith, MD, told symposium attendees yesterday at the 2014 Cooperative Meeting of CMSC and ACTRIMS in Dallas, TX…Â Read More |
 Robert T. Naismith, MD |
|
|
|
| Pursuing a Better Clinical Outcome Assessment To Measure Disease Progression, Disability in MS
The Multiple Sclerosis Outcome Assessment Consortium (MSOAC) is making progress in its work to identify a clinical outcome assessment that will reflect disease progression and that will be embraced and utilized by the broad community of multiple sclerosis (MS) researchers, clinicians, patients, advocates, and other stakeholders, Ellen M. Mowry, MD, MCR, reported yesterday at the 2014 Cooperative Meeting of CMSC and ACTRIMS in Dallas, TX…Â Read More |
 Ellen M. Mowry, MD, MCR |
© 2014, Delaware Media Group, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or Biogen Idec.
